| Patient | Joe Frazier |
|---|---|
| Date of birth | 1944-01-12 |
| Identifiers | MRN HR-BX004-SYN-TD; SSN (made up) 000-04-5590 |
| Document date | 2008-09-14 |
| Author | Clarence Whitfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Seven-month review with the six-month liver cancer surveillance ultrasound and AFP. [S]
Mr. Frazier returns nine weeks after his preventive visit. He has taken semaglutide 1 mg weekly for four months, with metformin, lisinopril, amlodipine and atorvastatin, without missed doses or side effects. Home readings average 124/78. He has had no alcohol since March. He has lost 6.8 kg since intake. He had the six-month liver ultrasound this morning. His PSA from the preventive visit was 1.4 ng/mL, which he was told by phone, and his colonoscopy is booked for next month. He has had no leg or abdominal swelling, black stools, confusion or yellowing. [S]
| Element | Detail |
|---|---|
| Semaglutide | 1 mg weekly for four months |
| Home blood pressure | Average 124/78 |
| Weight | 97.2 kg, down 6.8 kg (6.5%) |
| Alcohol | None since March |
| Screening | PSA 1.4 ng/mL; colonoscopy next month |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No abdominal swelling, black stools or nausea |
| Neurological | Negative | No confusion or sleep reversal |
| Cardiovascular | Negative | No ankle swelling |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years | One tablet twice daily with meals | Oral route | 2008-02-16 | active | S |
| Lisinopril 20 mg oral tablet, one tablet daily; taken for years | One tablet daily | Oral route | 2008-02-16 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2008-02-16 | active | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2008-03-02 to 2008-04-13 | completed | S |
| Amlodipine 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2008-04-13 | active | S |
| Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly | 0.25 mg weekly for four weeks, then 0.5 mg weekly | Subcutaneous route | 2008-03-02 to 2008-05-18 | completed | S |
| Semaglutide pen (1 mg per dose), 1 mg under the skin once weekly | 1 mg once weekly | Subcutaneous route | 2008-05-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2008-09-14 | Body height | 182 | cm | S |
| 2008-09-14 | Body weight | 97.2 | kg | S |
| 2008-09-14 | Body mass index (BMI) [Ratio] | 29.3 | kg/m2 | S |
| 2008-09-14 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2008-09-14 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2008-09-14 | Heart rate | 72 | /min | S |
| 2008-09-14 | Respiratory rate | 16 | /min | S |
| 2008-09-14 | Body temperature | 36.7 | Cel | S |
| 2008-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2008-09-14 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.8 | % | Below 5.7% is normal; goal below 7% for him | High | S |
| 2008-09-14 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2008-09-14 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2008-09-14 | Creatinine [Mass/volume] in Serum or Plasma | 1.06 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2008-09-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2003)/1.73 sq M | 78 | mL/min/{1.73_m2} | 60 or higher without kidney damage markers is not CKD | Normal | S |
| 2008-09-14 | Albumin/Creatinine [Mass Ratio] in Urine | 14 | mg/g | Below 30 mg/g is normal (A1) | Normal | S |
| 2008-09-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 | U/L | 10-40 U/L | Normal | S |
| 2008-09-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-55 U/L | Normal | S |
| 2008-09-14 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2008-09-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2008-09-14 | Platelets [#/volume] in Blood by Automated count | 140 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2008-09-14 | Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma | 4 | ng/mL | <=8.3 ng/mL | Normal | S |
Vital signs recorded on 2008-09-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 122/76, pulse 72; weight 97.2 kg, BMI 29.3 |
| Abdomen | Soft; no ascites |
| Skin | No jaundice |
| Neurological | No asterixis |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetes | active | confirmed | E11.65 | S — Synthetic modern diagnosis; diabetes was reported publicly during his life, but its duration and treatment here are synthetic. |
| Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressure | active | confirmed | I10 | S — Synthetic modern diagnosis; high blood pressure was reported publicly during his life. |
| Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluated | resolved | confirmed | R74.01 | S — Synthetic presenting finding, superseded at the two-week visit by the elastography and ultrasound diagnosis. |
| Metabolic dysfunction-associated steatotic liver disease (MASLD): steatosis on elastography (controlled attenuation parameter 318 dB/m) and ultrasound, with diabetes, obesity, low HDL and high triglycerides, and little alcohol | active | confirmed | K76.0 | S — Synthetic modern diagnosis. Not part of the public record of his life; chosen to teach surveillance. |
| Compensated cirrhosis (compensated advanced chronic liver disease) from MASLD: liver stiffness 17.6 kPa, platelets 138, nodular liver surface and a spleen of 13.4 cm on ultrasound; no ascites, encephalopathy, bleeding or jaundice; Child-Pugh A | active | confirmed | K74.69 | S — Synthetic modern diagnosis. Not part of the public record of his life; the liver cancer diagnosed three years later in the true frame does not appear in the modern episode. |
| Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statin | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Obesity, class 1 (BMI 31.4) | active | confirmed | E66.811 | S — Synthetic finding; described without stigma. |
| Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30 | active | confirmed | H54.62 | S — Synthetic modern measurement anchored to the documented cataract in his left eye. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Liver ultrasound with AFP for hepatocellular carcinoma surveillance | Every 6 months in cirrhosis | Completed today | Ultrasound: no focal lesion, no ascites, visualization score A; AFP 4.0 ng/mL; on schedule six months after the baseline |
| Laboratory | Liver function (albumin, bilirubin, INR, platelets; Child-Pugh and MELD) | At diagnosis, then every 6 months | Completed today | Albumin 4.1, bilirubin 0.8, platelets 140; Child-Pugh A |
| Laboratory | Liver tests with FIB-4 | Yearly with diabetes; FIB-4 1.3 or higher leads to elastography | Completed today | AST 38, ALT 31 U/L; FIB-4 3.12 |
| Imaging | Transient elastography | When FIB-4 is 1.3 or higher; repeat in 1 to 2 years | Due | Repeat at one year |
| Referral | Variceal screening | Endoscopy when portal hypertension cannot be ruled out; repeat in 2 years if no varices and the liver injury continues | Up to date | No varices in April; repeat in two years |
| Laboratory | Hemoglobin A1c | Every 3 months until at goal or after a change in treatment, then every 6 months | Completed today | 6.8%, at goal |
| Examination | Blood pressure (clinic and home), weight and BMI | Every visit | Completed today | 122/76 in the clinic; home average 124/78; weight 97.2 kg |
| Laboratory | Potassium, creatinine and eGFR (CKD-EPI 2003) on lisinopril | Every 6 months on an ACE inhibitor, and after changes | Completed today | Sodium 140, potassium 4.5, creatinine 1.06 mg/dL, eGFR 78 |
| Laboratory | Urine albumin-to-creatinine ratio | Yearly | Completed today | 14 mg/g |
| Examination | Dilated eye examination | At the start of care, then every 1 to 2 years; promptly when A1c is falling quickly on a GLP-1 receptor agonist | Up to date | Dilated examination in June: no diabetic retinopathy |
| Examination | Comprehensive foot examination | Yearly | Up to date | At intake; next in February |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin, then yearly | Up to date | LDL 68 mg/dL in April; yearly |
| Laboratory | Vitamin B12 on long-term metformin | Periodically on long-term metformin | Up to date | 340 pg/mL at intake |
| Medication safety | Aspirin for primary prevention | Yearly | Not indicated | Bleeding risk with cirrhosis outweighs benefit in primary prevention |
| Medication safety | Semaglutide dose steps, nausea, abdominal pain, gallbladder and pancreatitis symptoms | At each dose step | Completed today | 1 mg weekly; no side effects |
| Self-management | Alcohol abstinence | Every visit | Completed today | No alcohol since March |
| Self-management | Warning signs of decompensation (swelling, confusion, bleeding, jaundice) | Every visit | Completed today | Reviewed; none |
| Self-management | Vaccines for diabetes and chronic liver disease | As due | Completed today | Hepatitis A dose 2, second zoster dose, influenza, COVID-19 and RSV vaccines today |
Goal progress:
Immunizations given today: Hepatitis A vaccine, adult, dose 2 of 2; Recombinant zoster vaccine, dose 2 of 2; Influenza vaccine, inactivated, this season; COVID-19 vaccine, mRNA, this season; RSV vaccine, single dose [S]
Guideline basis: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023); AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023); Baveno VII - Renewing consensus in portal hypertension (2022); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026)
Follow-up: Visit in three months. Ultrasound with AFP in six months; hepatology visit with elastography at one year. A1c every six months. Colonoscopy next month. Preventive visit in one year. [S]